DVAX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: JNJ PFE MRNA GILD BNTX AZN REGN NVAX VIR VXRT

| Held by: IJR VTI IWM XBI VXF SPSM IWO IBB IJS VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.47	Insider Own	0.55%	Shs Outstand	117.23M	Perf Week	-6.46%
Market Cap	1.10B	Forward P/E	19.41	EPS next Y	0.48	Insider Trans	-76.38%	Shs Float	116.62M	Perf Month	-13.03%
Enterprise Value	779.32M	PEG	-	EPS next Q	0.13	Inst Own	96.80%	Short Float	12.09%	Perf Quarter	-9.52%
Income	-52.73M	P/S	3.49	EPS this Y	-318.39%	Inst Trans	-13.90%	Short Ratio	8.25	Perf Half Y	-31.26%
Sales	316.27M	P/B	2.23	EPS next Y	211.00%	ROA	-5.45%	Short Interest	14.10M	Perf YTD	-26.31%
Book/sh	4.22	P/C	1.80	EPS next 5Y	52.08%	ROE	-9.28%	52W High	14.63 -35.68%	Perf Year	-15.91%
Cash/sh	5.23	P/FCF	16.70	EPS past 3/5Y	-27.72% -	ROIC	-7.13%	52W Low	9.22 2.06%	Perf 3Y	-15.45%
Dividend Est.	-	EV/EBITDA	104.61	Sales past 3/5Y	-14.08% 51.08%	Gross Margin	82.83%	Volatility	2.98% 3.00%	Perf 5Y	92.83%
Dividend TTM	-	EV/Sales	2.46	EPS Y/Y TTM	-419.55%	Oper. Margin	-0.24%	ATR (14)	0.35	Perf 10Y	-67.63%
Dividend Ex-Date	-	Quick Ratio	6.01	Sales Y/Y TTM	26.66%	Profit Margin	-16.67%	RSI (14)	33.67	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	6.65	EPS Q/Q	65.00%	SMA20	-7.73%	Beta	1.14	Target Price	22.25
Payout	0.00%	Debt/Eq	0.59	Sales Q/Q	29.33%	SMA50	-11.14%	Rel Volume	0.97	Prev Close	9.74
Employees	405	LT Debt/Eq	0.50	Earnings	Aug 07 AMC	SMA200	-19.25%	Avg Volume	1.71M	Price	9.41
IPO	Feb 19, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.33% 10.13%	Trades		Volume	1,650,004	Change	-3.39%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Downgrade	Goldman	Neutral → Sell	$15 → $12
Feb-01-24	Initiated	Goldman	Neutral	$20
Sep-27-22	Initiated	JMP Securities	Mkt Outperform	$22
Jan-06-22	Resumed	Goldman	Buy	$38
Aug-06-21	Initiated	Goldman	Buy	$19
Aug-07-20	Reiterated	H.C. Wainwright	Buy	$14 → $12
Aug-03-20	Reiterated	H.C. Wainwright	Buy	$12 → $14
Jun-15-20	Initiated	Evercore ISI	Outperform	$14
Oct-18-19	Initiated	H.C. Wainwright	Buy	$13
Jul-11-19	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$20
Feb-27-19	Reiterated	Cantor Fitzgerald	Overweight	$32 → $28
May-10-18	Upgrade	JP Morgan	Neutral → Overweight
Mar-08-18	Reiterated	Cantor Fitzgerald	Overweight	$25 → $27
Feb-14-18	Downgrade	JP Morgan	Overweight → Neutral
Sep-25-17	Reiterated	RBC Capital Mkts	Outperform	$26 → $28
Sep-15-17	Initiated	Cantor Fitzgerald	Overweight	$24
Jul-31-17	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $26
Jul-31-17	Upgrade	JP Morgan	Neutral → Overweight
May-09-17	Reiterated	RBC Capital Mkts	Sector Perform	$6 → $7
Apr-28-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$48 → $17

Show Previous Ratings

Sep-02-25 04:05AM	Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook (Insider Monkey)
Aug-27-25 04:05PM	Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
Aug-22-25 07:25AM	Dynavaxs shingles vaccine shows promise in trial against GSKs Shingrix (Clinical Trials Arena)
Aug-21-25 08:00AM	Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile (PR Newswire) +5.09%
Aug-07-25 05:10PM	Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates (Zacks) -6.60%
04:11PM	Loading…
04:11PM	Dynavax Technologies: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Dynavax Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-06-25 05:25PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-29-25 04:02PM	Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 (PR Newswire)
Jul-28-25 05:20PM	Exelixis (EXEL) Beats Q2 Earnings Estimates (Zacks)
Jul-06-25 04:15AM	Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31 (Insider Monkey)
Jun-11-25 11:01AM	Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting (PR Newswire)
Jun-09-25 08:30AM	Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom (Business Wire)
07:30AM	Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting (PR Newswire)
Jun-04-25 04:59PM	Dynavax Comments on Glass Lewis Recommendation (PR Newswire)
09:27AM	Loading…
09:27AM	Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies (Business Wire)
May-28-25 04:10PM	Dynavax to Present at William Blair's 45th Annual Growth Stock Conference (PR Newswire)
May-23-25 06:12PM	Deep Track Capital Comments on ISS Recommendation (Business Wire)
01:44PM	Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees (PR Newswire)
May-15-25 04:00PM	Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting (Business Wire)
May-12-25 07:30AM	Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value (PR Newswire)
May-09-25 08:38PM	/C O R R E C T I O N -- Dynavax Technologies/ (PR Newswire)
May-08-25 12:00PM	Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why (Zacks)
May-07-25 04:45PM	Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum (PR Newswire) -10.99%
03:19AM	Dynavax Technologies Corp (DVAX) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
May-06-25 05:15PM	Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs (PR Newswire)
08:00AM	Deep Track Capital Releases Investor Presentation on Dynavax Technologies (Business Wire)
May-05-25 08:10AM	TG Therapeutics (TGTX) Lags Q1 Earnings Estimates (Zacks)
May-01-25 08:00AM	Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits (PR Newswire)
07:30AM	Loading…
Apr-29-25 07:30AM	Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy (PR Newswire)
Apr-22-25 04:00PM	Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 (PR Newswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Apr-17-25 09:17AM	GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP (Zacks)
07:15AM	Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders (PR Newswire)
Apr-16-25 09:48AM	MURA Soars as it Explores Strategic Options Post Cancer Study Failures (Zacks) -6.66%
08:52AM	DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up (Zacks)
08:00AM	Deep Track Capital Comments on Dynavax Technologies Rejection of Most Recent Settlement Offer (Business Wire)
Apr-15-25 10:20AM	Buy The Dips, Sell The Rips (Seeking Alpha)
Apr-11-25 11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 10:53AM	PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose (Zacks) -8.81%
09:58AM	ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up (Zacks)
Apr-09-25 12:57PM	3 Biotech Stocks Holding Their Own (Seeking Alpha)
10:01AM	RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study (Zacks)
Apr-08-25 12:18PM	AtriCure Drops 25%: Bargain Or Caution Sign? (Seeking Alpha) -5.92%
11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
Apr-07-25 10:53AM	AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs (Zacks)
Apr-04-25 01:45PM	Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study (Zacks)
01:10PM	AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication (Zacks)
09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks)
Apr-03-25 05:40PM	Dynavax Files Preliminary Proxy Statement (PR Newswire)
11:27AM	SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases (Zacks)
09:32AM	DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up (Zacks)
Apr-02-25 11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
Apr-01-25 10:55AM	VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates (Zacks)
09:31AM	AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication (Zacks)
Mar-31-25 09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance) -5.19%
Mar-28-25 09:45AM	Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
09:26AM	BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance (Zacks)
Mar-27-25 12:37PM	Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma (Zacks)
09:39AM	PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know (Zacks)
Mar-25-25 12:44PM	Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? (Zacks)
11:51AM	UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study (Zacks)
Mar-24-25 02:36PM	EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD (Zacks)
Mar-21-25 12:46PM	Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy (Zacks)
12:44PM	OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek (Zacks)
12:39PM	Pacira Surges 66.8% in Six Months: How Should You Play the Stock? (Zacks)
12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
12:17PM	PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug (Zacks)
09:26AM	ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia (Zacks)
Mar-20-25 12:23PM	Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why (Zacks)
10:44AM	Why Dynavax Technologies (DVAX) Stock Might be a Great Pick (Zacks)
10:19AM	IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success (Zacks)
09:34AM	Novartis Reports Updated Positive Data From Phase III SMA Program (Zacks)
Mar-19-25 10:59AM	JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease (Zacks)
Mar-12-25 09:55AM	Wall Street Analysts See an 83.1% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High? (Zacks)
Mar-10-25 08:00AM	Deep Track Capital Sends Letter to Dynavax Technologies Board of Directors (Business Wire)
Mar-06-25 06:00AM	Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase (PR Newswire)
Mar-02-25 12:36PM	Is Dynavax Technologies Corporation (DVAX) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-25-25 04:10PM	Dynavax to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-24-25 09:55AM	Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet (Zacks)
Feb-21-25 12:59PM	MercadoLibre Stock Hits New High As Company Delivers Profits (Investor's Business Daily)
02:14AM	Dynavax Technologies Corp (DVAX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-20-25 09:30PM	Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript (Motley Fool)
05:10PM	Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:15PM	Dynavax Technologies: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance (PR Newswire)
Feb-19-25 04:52PM	Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy (PR Newswire)
09:00AM	Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies Board of Directors at 2025 Annual Meeting (Business Wire)
08:04AM	Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors (Reuters)
Feb-11-25 03:11PM	Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty (Benzinga)
Feb-06-25 05:42PM	Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025 (PR Newswire)
Jan-29-25 09:55AM	Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 93.2%: Here's is How to Trade (Zacks)
Jan-27-25 06:00AM	Dynavax Advances Board Refreshment Program (PR Newswire)
Jan-16-25 12:00PM	Dynavax Technologies (DVAX) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-14-25 09:29AM	Dynavax Reports Revenue Growth and Defense Contract (TipRanks)
Jan-13-25 09:00AM	Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights (PR Newswire)
Jan-03-25 08:30AM	Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options (Zacks)
Nov-27-24 09:55AM	Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect? (Zacks)

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Myers Scott Dunseth	Director	Aug 22 '25	Buy	10.82	3,800	41,116	35,004	Aug 25 08:50 AM
Deep Track Biotechnology Maste	10% Owner	Aug 21 '25	Sale	11.03	1,094,994	12,077,784	16,696,492	Aug 22 08:49 PM
Deep Track Biotechnology Maste	10% Owner	Aug 22 '25	Sale	10.59	970,143	10,273,814	15,726,349	Aug 22 08:49 PM
Novack David F	President & COO	Mar 24 '25	Option Exercise	6.80	10,000	68,050	18,078	Mar 26 05:04 PM
Novack David F	President & COO	Mar 24 '25	Sale	14.00	10,000	140,000	8,078	Mar 26 05:04 PM
DAVID NOVACK	Officer	Mar 24 '25	Proposed Sale	14.00	10,000	140,000		Mar 24 04:23 PM
Novack David F	President & COO	Mar 18 '25	Sale	13.58	14,020	190,392	8,078	Mar 20 06:15 PM
DAVID NOVACK	Officer	Mar 18 '25	Proposed Sale	13.58	14,020	190,386		Mar 18 04:17 PM
Novack David F	President & COO	Mar 07 '25	Sale	14.39	32,764	471,474	22,098	Mar 10 09:44 PM
DAVID NOVACK	Officer	Mar 07 '25	Proposed Sale	14.39	32,764	471,376		Mar 07 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Dynavax Technologies Corp

Upgrade your FINVIZ experience